These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 26216709)

  • 41. Growth hormone receptor modulators.
    Birzniece V; Sata A; Ho KK
    Rev Endocr Metab Disord; 2009 Jun; 10(2):145-56. PubMed ID: 18622706
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inhibition of growth hormone receptor activation by pegvisomant may increase bone density in acromegaly.
    Jimenez C; Ayala-Ramirez M; Liu J; Nunez R; Gagel RF
    Horm Metab Res; 2011 Jan; 43(1):55-61. PubMed ID: 21104581
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Growth Hormone Resistance-Special Focus on Inflammatory Bowel Disease.
    Soendergaard C; Young JA; Kopchick JJ
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28486400
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
    Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
    Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term effects of pegvisomant in patients with acromegaly.
    Hodish I; Barkan A
    Nat Clin Pract Endocrinol Metab; 2008 Jun; 4(6):324-32. PubMed ID: 18431372
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Does pegvisomant treatment expertise improve control of resistant acromegaly? The Italian ACROSTUDY experience.
    Cannavo S; Bogazzi F; Colao A; De Marinis L; Maffei P; Gomez R; Graziano E; Monterubbianesi M; Grottoli S;
    J Endocrinol Invest; 2015 Oct; 38(10):1099-109. PubMed ID: 25916431
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Expression of the growth hormone/insulin-like growth factor axis during Balb/c thymus ontogeny and effects of growth hormone upon ex vivo T cell differentiation.
    Kermani H; Goffinet L; Mottet M; Bodart G; Morrhaye G; Dardenne O; Renard C; Overbergh L; Baron F; Beguin Y; Geenen V; Martens HJ
    Neuroimmunomodulation; 2012; 19(3):137-47. PubMed ID: 22261974
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Growth hormone and glucose metabolism: the model of the GH-receptor antagonists.
    Van der Lely AJ
    Ann Endocrinol (Paris); 2004 Feb; 65(1):81-3. PubMed ID: 15122098
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study.
    Filopanti M; Olgiati L; Mantovani G; Corbetta S; Arosio M; Gasco V; De Marinis L; Martini C; Bogazzi F; Cannavò S; Colao A; Ferone D; Arnaldi G; Pigliaru F; Peri A; Angeletti G; Jaffrain-Rea ML; Lania AG; Spada A
    J Clin Endocrinol Metab; 2012 Feb; 97(2):E165-72. PubMed ID: 22162472
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.
    Sesmilo G; Fairfield WP; Katznelson L; Pulaski K; Freda PU; Bonert V; Dimaraki E; Stavrou S; Vance ML; Hayden D; Klibanski A
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1692-9. PubMed ID: 11932303
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of acromegaly with pegvisomant during pregnancy: maternal and fetal effects.
    Brian SR; Bidlingmaier M; Wajnrajch MP; Weinzimer SA; Inzucchi SE
    J Clin Endocrinol Metab; 2007 Sep; 92(9):3374-7. PubMed ID: 17595256
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of streptozotocin treatment in growth hormone (GH) and GH antagonist transgenic mice.
    Chen NY; Chen WY; Bellush L; Yang CW; Striker LJ; Striker GE; Kopchick JJ
    Endocrinology; 1995 Feb; 136(2):660-7. PubMed ID: 7835300
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Growth hormone in vascular pathology: neovascularization and expression of receptors is associated with cellular proliferation.
    Lincoln DT; Singal PK; Al-Banaw A
    Anticancer Res; 2007; 27(6B):4201-18. PubMed ID: 18225592
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Regulation of growth-hormone-receptor gene expression by growth hormone and pegvisomant in human mesangial cells.
    Meinhardt U; Eblé A; Besson A; Strasburger CJ; Sraer JD; Mullis PE
    Kidney Int; 2003 Aug; 64(2):421-30. PubMed ID: 12846737
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Growth hormone receptor antagonism suppresses tumour regrowth after radiotherapy in an endometrial cancer xenograft model.
    Evans A; Jamieson SM; Liu DX; Wilson WR; Perry JK
    Cancer Lett; 2016 Aug; 379(1):117-23. PubMed ID: 27241667
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of pituitary tumors: pegvisomant.
    Paisley AN; Drake WM
    Endocrine; 2005 Oct; 28(1):111-4. PubMed ID: 16311417
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of a GH receptor antagonist (GHRA) to explore the relationship between GH and IGF-I in adults with severe GH deficiency (GHD).
    Berg CA; Pokrajac A; Bidlingmaier M; Strasburger CJ; Shalet SM; Trainer PJ
    Clin Endocrinol (Oxf); 2009 Mar; 70(3):439-45. PubMed ID: 19067728
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The future of growth hormone antagonists.
    van der Lely AJ
    Curr Opin Pharmacol; 2002 Dec; 2(6):730-3. PubMed ID: 12482738
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice.
    McCutcheon IE; Flyvbjerg A; Hill H; Li J; Bennett WF; Scarlett JA; Friend KE
    J Neurosurg; 2001 Mar; 94(3):487-92. PubMed ID: 11235955
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis.
    Biering H; Saller B; Bauditz J; Pirlich M; Rudolph B; Johne A; Buchfelder M; Mann K; Droste M; Schreiber I; Lochs H; Strasburger CJ;
    Eur J Endocrinol; 2006 Feb; 154(2):213-20. PubMed ID: 16452533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.